VYGR - Voyager Therapeutics Inc Stock Price, Fair Value and News

7.85USD-0.13 (-1.63%)Market Closed

Market Summary

USD7.85-0.13

Market Closed

-1.63%

VYGR Alerts

1 major insider sales recently.

VYGR Stock Price

View Fullscreen

VYGR RSI Chart

VYGR Valuation

Market Cap

433.3M

Price/Earnings (Trailing)

3.27

Price/Sales (Trailing)

1.73

EV/EBITDA

2.64

Price/Free Cashflow

5.8

VYGR Price/Sales (Trailing)

VYGR Profitability

EBT Margin

53.49%

Return on Equity

56%

Return on Assets

37.67%

Free Cashflow Yield

17.23%

VYGR Fundamentals

VYGR Revenue

Revenue (TTM)

250.0M

Rev. Growth (Yr)

-5.97%

Rev. Growth (Qtr)

1.9K%

VYGR Earnings

Earnings (TTM)

132.3M

Earnings Growth (Yr)

338.7%

Earnings Growth (Qtr)

317.73%

Breaking Down VYGR Revenue

52 Week Range

7.88

(Low)(High)

Last 7 days

-12.2%

Last 30 days

-14.0%

Last 90 days

9.3%

Trailing 12 Months

0.8%

How does VYGR drawdown profile look like?

VYGR Financial Health

Current Ratio

4.96

VYGR Investor Care

Shares Dilution (1Y)

25.42%

Diluted EPS (TTM)

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	93.2M	145.5M	197.7M	250.0M
2022	38.3M	39.2M	40.0M	40.9M
2021	159.6M	132.2M	15.9M	37.4M
2020	117.3M	99.9M	197.3M	171.1M
2019	11.9M	55.4M	73.7M	104.4M
2018	9.6M	11.0M	12.0M	7.6M
2017	10.9M	8.3M	6.2M	10.1M
2016	19.6M	18.4M	16.8M	14.2M
2015	0	0	0	17.3M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Voyager Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	sandrock alfred	sold	-119,454	9.86	-12,115	president and ceo
Apr 02, 2024	swartz robin	sold	-13,407	9.88	-1,357	chief operating officer
Apr 01, 2024	ferguson toby	acquired	-	-	105,000	chief medical officer
Feb 21, 2024	carter todd alfred	sold	-25,136	7.47	-3,365	chief scientific officer
Feb 21, 2024	sandrock alfred	sold	-97,226	7.46	-13,033	president and ceo
Feb 21, 2024	pfreundschuh peter p.	sold	-28,079	7.46	-3,764	chief financial officer
Feb 21, 2024	swartz robin	sold	-29,546	7.45	-3,966	chief operating officer
Feb 20, 2024	carter todd alfred	sold	-4,623	7.68	-602	chief scientific officer
Feb 09, 2024	carter todd alfred	acquired	-	-	38,500	chief scientific officer
Feb 09, 2024	swartz robin	acquired	-	-	50,000	chief operating officer

Which funds bought or sold VYGR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 05, 2024	GAMMA Investing LLC	added	33.56	770	1,853	-%
Apr 05, 2024	CWM, LLC	added	88.35	10,000	20,000	-%
Mar 11, 2024	VANGUARD GROUP INC	added	1.92	2,115,230	21,350,400	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	155	1,945,150	3,038,820	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	10,397	133,242	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	reduced	-14.42	-619,000	8,481,000	-%
Feb 15, 2024	Legal & General Group Plc	unchanged	-	2,974	36,360	-%
Feb 15, 2024	State of Wyoming	added	29.62	65,444	224,428	0.04%
Feb 15, 2024	BARCLAYS PLC	added	261	418,000	559,000	-%
Feb 14, 2024	Voya Investment Management LLC	unchanged	-	9,155	111,982	-%

Are Funds Buying or Selling VYGR?

Are funds buying VYGR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VYGR

No. of Funds

VYGR Alerts

1 major insider sales recently.

Unveiling Voyager Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.63%	4,236,000	SC 13G/A
Feb 14, 2024	third rock ventures iii, l.p.	0%	0	SC 13G/A
Feb 13, 2024	vanguard group inc	5.75%	2,529,668	SC 13G/A
Jan 29, 2024	blackrock inc.	6.0%	2,632,679	SC 13G
Feb 24, 2023	neurocrine biosciences inc	19.9%	8,575,316	SC 13D/A
Feb 14, 2023	armistice capital, llc	8.80%	3,396,000	SC 13G
Feb 14, 2023	third rock ventures iii, l.p.	14.1%	5,428,933	SC 13G/A
Feb 09, 2023	vanguard group inc	5.06%	1,955,172	SC 13G/A
Jan 13, 2023	ecor1 capital, llc	9.98%	3,851,507	SC 13G/A
Apr 26, 2022	ecor1 capital, llc	11.1%	4,276,507	SC 13G/A

Recent SEC filings of Voyager Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 02, 2024	144	Notice of Insider Sale Intent
Apr 02, 2024	144	Notice of Insider Sale Intent
Apr 02, 2024	8-K	Current Report
Mar 26, 2024	3	Insider Trading
Mar 26, 2024	4	Insider Trading
Mar 13, 2024	8-K	Current Report
Feb 28, 2024	10-K	Annual Report

Peers (Alternatives to Voyager Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	-0.04%	-27.89%	-8.41	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.5B	1.8B	-1.63%	-28.69%	-42.01	10.12	76.23%	61.08%
BMRN	17.2B	2.4B	8.39%	-9.36%	102.31	7.09	15.42%	18.43%
INCY	11.9B	3.7B	-8.82%	-29.04%	20	3.23	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-8.69%	-36.86%	-11.82	15.75	425.83%	18.94%
BBIO	4.4B	-	-8.20%	68.33%	-6.81	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-8.92%	-2.36%	-13.62	12.04	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.30%	-24.47%	-9.88	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-11.77%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.36%	-14.10%	25.63	4.6	85.90%	-14.05%
NVAX	557.0M	983.7M	-24.76%	-57.93%	-1.02	0.57	-50.36%	17.16%
CRBP	432.8M	881.7K	-5.56%	294.36%	-9.7	466.16	-77.61%	-5.33%
INO	225.3M	4.9M	-10.24%	-14.54%	-1.67	46.29	-54.97%	51.72%
IBIO	6.8M	2.1M	86.67%	92.16%	-0.25	2.14	-13.45%	66.37%

Voyager Therapeutics Inc News

Latest updates

Voyager Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	1851.9%	90,061	4,614	4,853	150,480	95,783	41,086	36,749	32,411	28,074	1,482	1,357	6,501	6,537	117,843	28,681	18,067	32,674	20,433	46,087	5,197	2,008
Operating Expenses	5.5%	35,998	34,121	30,279	27,596	23,013	26,644	20,079	22,008	22,372	26,628	29,942	32,090	30,266	33,316	37,662	42,500	46,442	38,240	36,898	34,490	25,169
S&GA Expenses	24.0%	10,242	8,258	8,294	9,028	8,462	7,307	7,552	7,659	8,351	8,714	10,437	9,744	8,270	8,277	8,239	10,206	9,891	8,463	8,322	9,659	8,256
R&D Expenses	-0.4%	25,756	25,863	21,985	18,568	14,551	19,337	12,527	14,349	14,021	17,914	19,505	22,346	21,997	25,039	29,423	32,294	36,551	29,777	28,576	24,831	16,914
EBITDA Margin	92.2%	0.55*	0.29*	0.69*	1.12*	-0.98*	-1.61*	-1.65*	-1.68*	-1.76*	2.61*	0.31*	0.26*	-	-	-	-	-	-	-	-	-
Income Taxes	564.4%	822	-177	59.00	704	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	319.4%	57,217	-26,078	-22,149	124,748	-23,610	17,624	-19,087	-21,319	-	-	-	-	-	-	-	-	-12,574	-15,006	11,153	-27,170	-22,531
EBT Margin	99.9%	0.53*	0.27*	0.66*	1.07*	-1.13*	-1.78*	-1.82*	-1.86*	-1.90*	2.31*	0.28*	0.23*	-	-	-	-	-	-	-	-	-
Net Income	317.7%	56,395	-25,901	-22,208	124,044	-23,626	17,624	-19,087	-21,319	5,709	-25,137	-30,120	-21,649	-15,926	85,611	-8,681	-24,263	-12,574	-15,006	11,153	-27,170	-22,532
Net Income Margin	100.1%	0.53*	0.26*	0.66*	1.06*	-1.13*	-0.43*	-1.53*	-1.85*	-1.90*	-5.85*	0.14*	0.25*	-	-	-	-	-	-	-	-	-
Free Cashflow	-12.3%	-24,515	-21,833	-2,045	123,056	-13,177	-16,484	-19,727	34,388	10,848	-21,369	-22,944	-21,669	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	19.2%	351	295	316	336	159	182	189	224	194	185	209	238	262	270	297	323	355	376	389	411	177
Current Assets	22.1%	320	262	282	303	124	147	152	171	137	126	149	176	198	216	247	272	305	328	341	365	162
Cash Equivalents	5.4%	69.00	65.00	244	268	99.00	98.00	80.00	132	117	113	120	118	106	149	146	165	87.00	83.00	81.00	113	48.00
Net PPE	-3.6%	16.00	17.00	17.00	17.00	18.00	18.00	19.00	19.00	22.00	23.00	24.00	25.00	25.00	23.00	20.00	19.00	18.00	15.00	14.00	13.00	13.00
Liabilities	-2.9%	115	118	117	119	100	103	129	148	99.00	97.00	98.00	102	107	104	221	243	255	268	270	311	131
Current Liabilities	4.6%	65.00	62.00	45.00	20.00	73.00	73.00	98.00	102	51.00	27.00	25.00	25.00	27.00	42.00	68.00	73.00	76.00	80.00	69.00	59.00	32.00
Shareholder's Equity	34.1%	236	176	199	217	59.00	80.00	60.00	76.00	95.00	87.00	111	136	154	166	77.00	80.00	100	108	118	101	46.00
Retained Earnings	17.8%	-261	-317	-291	-269	-393	-369	-387	-368	-347	-352	-327	-297	-275	-259	-345	-336	-312	-300	-285	-296	-269
Additional Paid-In Capital	0.7%	498	494	491	487	453	450	448	445	442	440	438	434	430	426	422	416	412	408	403	397	316
Shares Outstanding	0.3%	44.00	44.00	44.00	43.00	39.00	39.00	38.00	38.00	38.00	38.00	38.00	38.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	489	-	-	-	114	-	-	-	103	-	-	-	292	-	-	-	686	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-12.9%	-23,760	-21,051	-835	123,565	-12,244	-16,206	-18,485	34,426	11,195	-20,709	-22,717	-21,294	-21,977	-24,740	-21,201	-28,798	-23,360	-21,579	-31,557	125,162	-24,348
Share Based Compensation	5.8%	3,045	2,878	2,672	2,558	2,346	2,189	2,490	2,319	1,654	2,078	3,991	3,601	3,502	3,532	3,860	4,040	3,520	3,349	5,253	3,518	2,638
Cashflow From Investing	117.0%	26,833	-158,304	-24,663	14,491	14,067	34,722	-36,130	-19,998	-5,464	14,340	22,405	34,625	-21,516	27,356	-1,838	108,993	26,462	22,610	-2,888	-136,661	28,630
Cashflow From Financing	39.0%	460	331	1,548	31,306	276	15.00	807	12.00	227	-	357	28.00	486	510	2,133	34.00	300	1,724	1,069	77,901	435

VYGR Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Consolidated Statements of Operations and Comprehensive Income (Loss)
Collaboration revenue	$ 250,008	$ 40,907	$ 37,415
Operating expenses:
Research and development	92,172	60,764	73,787
General and administrative	35,822	30,980	37,246
Total operating expenses	127,994	91,744	111,033
Operating income (loss)	122,014	(50,837)	(73,618)
Other income, net:
Interest income (expense)	11,721	1,792	(390)
Other income	3	2,653	2,811
Total other income, net	11,724	4,445	2,421
Income (loss) before income taxes	133,738	(46,392)	(71,197)
Income tax provision	1,408	16
Net income (loss)	132,330	(46,408)	(71,197)
Other comprehensive income (loss)
Net unrealized gain (loss) on available-for-sale-securities	171	(81)	(4)
Total other comprehensive income (loss)	171	(81)	(4)
Comprehensive income (loss)	$ 132,501	$ (46,489)	$ (71,201)
Net income (loss) per share, basic	$ 3.08	$ (1.21)	$ (1.89)
Net income (loss) per share, diluted	$ 2.97	$ (1.21)	$ (1.89)
Weighted-average common shares outstanding, basic	43,020,747	38,356,810	37,668,947
Weighted-average common shares outstanding, diluted	44,569,334	38,356,810	37,668,947

VYGR Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 68,802	$ 98,959
Marketable securities	162,073	19,889
Accounts receivable	80,150
Related party collaboration receivable	3,341	257
Prepaid expenses and other current assets	5,318	5,394
Total current assets	319,684	124,499
Property and equipment, net	16,494	17,857
Deposits and other non-current assets	1,593	1,515
Operating lease, right-of-use assets	13,510	15,485
Total assets	351,281	159,356
Current liabilities:
Accounts payable	1,604	2,566
Accrued expenses	16,823	7,816
Other current liabilities	3,200	2,832
Deferred revenue, current	42,881	59,377
Total current liabilities	64,508	72,591
Deferred revenue, non-current	32,359	6,450
Other non-current liabilities	18,094	21,295
Total liabilities	114,961	100,336
Commitments, contingencies, and other liabilities (see note 8)
Stockholders' equity:
Preferred stock, $0.001 par value: 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022
Common stock, $0.001 par value: 120,000,000 shares authorized; 44,038,333 and 38,613,891 shares issued and outstanding at December 31, 2023 and 2022, respectively	44	38
Additional paid-in capital	497,506	452,713
Accumulated other comprehensive loss	(48)	(219)
Accumulated deficit	(261,182)	(393,512)
Total stockholders' equity	236,320	59,020
Total liabilities and stockholders' equity	$ 351,281	$ 159,356

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
WEBSITE	voyagertherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	125

Voyager Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Voyager Therapeutics Inc? What does VYGR stand for in stocks?

VYGR is the stock ticker symbol of Voyager Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Voyager Therapeutics Inc (VYGR)?

As of Tue Apr 16 2024, market cap of Voyager Therapeutics Inc is 433.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VYGR stock?

You can check VYGR's fair value in chart for subscribers.

What is the fair value of VYGR stock?

You can check VYGR's fair value in chart for subscribers. The fair value of Voyager Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Voyager Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VYGR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Voyager Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether VYGR is over valued or under valued. Whether Voyager Therapeutics Inc is cheap or expensive depends on the assumptions which impact Voyager Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VYGR.

What is Voyager Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, VYGR's PE ratio (Price to Earnings) is 3.27 and Price to Sales (PS) ratio is 1.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VYGR PE ratio will change depending on the future growth rate expectations of investors.